Medincell Sa Stock EBITDA
| MEDCL Stock | EUR 17.42 0.26 1.52% |
Medincell SA fundamentals help investors to digest information that contributes to Medincell's financial success or failures. It also enables traders to predict the movement of Medincell Stock. The fundamental analysis module provides a way to measure Medincell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medincell stock.
Medincell |
Medincell SA Company EBITDA Analysis
Medincell's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Medincell EBITDA | (21.45 M) |
Most of Medincell's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medincell SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Medincell SA reported earnings before interest,tax, depreciation and amortization of (21.45 Million). This is 102.44% lower than that of the Healthcare sector and 121.41% lower than that of the Biotechnology industry. The ebitda for all France stocks is 100.55% higher than that of the company.
Medincell EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medincell's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medincell could also be used in its relative valuation, which is a method of valuing Medincell by comparing valuation metrics of similar companies.Medincell is currently under evaluation in ebitda category among its peers.
Medincell Fundamentals
| Return On Asset | -0.4 | |||
| Operating Margin | (3.25) % | |||
| Current Valuation | 180.29 M | |||
| Shares Outstanding | 25.22 M | |||
| Shares Owned By Insiders | 47.40 % | |||
| Shares Owned By Institutions | 18.95 % | |||
| Price To Book | 27.59 X | |||
| Price To Sales | 20.97 X | |||
| Revenue | 4.09 M | |||
| Gross Profit | 4.09 M | |||
| EBITDA | (21.45 M) | |||
| Net Income | (24.81 M) | |||
| Cash And Equivalents | 5 M | |||
| Cash Per Share | 1.24 X | |||
| Total Debt | 16.25 M | |||
| Debt To Equity | 4.61 % | |||
| Current Ratio | 4.14 X | |||
| Book Value Per Share | (1.04) X | |||
| Cash Flow From Operations | (21.36 M) | |||
| Earnings Per Share | (1.12) X | |||
| Target Price | 14.0 | |||
| Number Of Employees | 151 | |||
| Beta | 1.02 | |||
| Market Capitalization | 215.89 M | |||
| Total Asset | 44.3 M | |||
| Z Score | 7.8 | |||
| Net Asset | 44.3 M |
About Medincell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medincell SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medincell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medincell SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Medincell Stock Analysis
When running Medincell's price analysis, check to measure Medincell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medincell is operating at the current time. Most of Medincell's value examination focuses on studying past and present price action to predict the probability of Medincell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medincell's price. Additionally, you may evaluate how the addition of Medincell to your portfolios can decrease your overall portfolio volatility.